Longevity & Aging
metformin increases lifespan
In plain terms: Is metformin proven to extend healthy human lifespan?
Part of: 💊 metformin
No — the definitive trial (TAME) has not reported outcomes and existing human evidence is indirect/confounded, so "fuzzy/inconclusive" is accurate; corroborates the vault's existing contested state.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Rests on the confounded Bannister-2014 observation (diabetics on metformin outliving non-diabetic controls); metformin alone was NULL in the NIA ITP mice; no completed healthy-human RCT (TAME unrun). Unproven for non-diabetic longevity.
The evidence (20)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Han 2026 · Biomedicines | observational | mixed | low | Review frames metformin as 'therapeutic paradox': geroprotective signals vs potential sarcopenia/muscle harm; net longevity unproven |
| Xiao 2022 · Aging Cell | animal | supports | moderate | Metformin extends C. elegans healthspan via SAM restriction/H3K4me3 modifiers; non-mammalian model, mechanism-level |
| Cedillo 2023 · eLife | animal | supports | moderate | Biguanide/metformin pro-longevity in C. elegans requires ether lipid biosynthesis; model-organism mechanism, not human |
| Corley 2024 · Aging Cell | observational | mixed | low | Retrospective trial analysis: metformin reversed monocyte epigenetic age in virally-suppressed older PLWH; cell-type-specific, small |
| Kulkarni AS 2020 · Aging (Albany) | mechanism | tested-null | low | Metformin blunts skeletal-muscle transcriptome adaptation to resistance training in older adults; undercuts healthy-aging benefit |
| Li 2021 · Eur J Clin Invest | meta-analysis | mixed | high | Umbrella review: metformin mortality/longevity associations are low-credibility |
| Strong 2016 · Aging Cell | animal | contradicts | high | [FT-verified] FT NIA-ITP metformin alone did NOT extend lifespan; only +rapamycin did |
| Nwanaji-Enwerem 2021 · Clinical Epigenetics | RCT | tested-null | low | Post-hoc RCT in overweight breast-cancer survivors: metformin showed no significant effect on epigenetic age measures vs placebo |
| Long 2017 · Trials | RCT | tested-null | low | HUMAN: MASTERS RCT protocol; the trial found metformin BLUNTED resistance-training muscle hypertrophy in seniors — a cost cutting against blanket geroprotection. |
| Onken 2022 · Aging Cell | animal | mixed | moderate | Across Caenorhabditis species metformin lifespan benefit is genetic-background dependent; not universal, sometimes toxic |
| Zajda 2020 · Mech Ageing Dev | mechanism | mixed | low | Review: animal/cell data suggest geroprotection but human lifespan effect remains hypothetical, awaiting TAME |
| Morin J 2024 · Aging Cell | observational | contradicts | moderate | Retrospective analysis of >500,000 UK Biobank-scale participants aged 40-70: metformin use was NOT associated with extended lifespan/reduced all-cause mortality in the general population — large observational evidence against a non-diabetic longevity benefit. |
| Madsen 2019 · Cochrane Database Syst Rev | meta-analysis | contradicts | high | Cochrane: no firm evidence metformin reduces all-cause or CV mortality in people at risk of T2D |
| Yang 2024 · Cell | animal | supports | high | 40-month study: metformin decelerates multiple aging-clock/tissue markers in male cynomolgus monkeys; strongest primate support, non-human |
| Monami 2021 · Nutr Metab Cardiovasc Dis | meta-analysis | mixed | high | Updated RCT meta-analysis: metformin no significant effect on all-cause mortality or MACE in T2D; benefit not established |
| Bannister 2014 · Diabetes Obes Metab | observational | supports | low | [FT-verified] CPRD confounded survivor/prescribing bias; not lifespan-extension proof |
| Murillo-Cancho 2025 · Int J Mol Sci | observational | tested-null | low | HUMAN review: classes metformin as a CR-mimetic whose long-term safety and efficacy in healthy populations remain incompletely defined; hard outcomes (frailty, mortality) unproven — matches inconclusive. |
| Stevens 2012 · Diabetologia | meta-analysis | mixed | high | Collaborative RCT meta-analysis: no clear all-cause mortality or cancer reduction from metformin vs comparators; modest/uncertain |
| Malin 2026 · J Clin Endocrinol Metab | RCT | contradicts | moderate | Metformin blunts vascular insulin-sensitivity gains after exercise training in at-risk adults; interferes with exercise adaptation |
| Newman 2019 · J Clin Endocrinol Metab | RCT | contradicts | moderate | Notes metformin attenuates favorable physiological adaptations to endurance exercise; counters geroprotective framing in healthy people |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.